Two Boston-area biotechs focused on kidney disease, Keryx and Akebia, to merge

Two Boston-area biotech firms that specialize in drugs for chronic kidney disease — Cambridge-based Akebia Therapeutics and Boston-based Keryx Biopharmaceuticals — will merge and form a company worth $1.3 billion. On Thursday morning, the two companies announced that both boards have approved the plan. The combined company will be named Akebia Therapeutics (Nasdaq: AKBA) and will be led by that company’s CEO, John Butler. The two companies would have more than 300 combined employees, barring…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Source Type: news

Related Links:

Authors: Lorenzo Sellarés V Abstract This review discusses the diagnostic value of urinary parameters in the setting of advanced chronic kidney disease and we present the key concepts that summarise the suggestions of the manuscript. URINARY VOLUME: The amount of fluid intake may be a non-established risk factor for CKD. For these patients, a urinary output ≥2-3 l/day is a reasonable proposal. This recommendation is not applicable to patients with cardiorenal syndrome or fluid overload risk. NA: This determination is very useful to monitor salt intake. Reducing urinary Na
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - Category: Urology & Nephrology Tags: Nefrologia Source Type: research
Authors: Sabbag A, Yao X, Siontis KC, Noseworthy PA Abstract The burden of atrial fibrillation (AF) is projected to increase substantially over the next decade in parallel with the aging of the population. The increasing age, level of comorbidity, and polypharmacy will complicate the treatment of older adults with AF. For instance, advanced age and chronic kidney disease have been shown to increase the risk of both thromboembolism and bleeding in patients with AF. Frailty, recurrent falls and polypharmacy, while very common among elderly patients with AF, are often overlooked in the clinical decision making despite...
Source: Korean Circulation Journal - Category: Cardiology Tags: Korean Circ J Source Type: research
Source: Internal and Emergency Medicine - Category: Emergency Medicine Source Type: research
Publication date: Available online 20 September 2018Source: Biosensors and BioelectronicsAuthor(s): C.S. Pundir, Seema Jakhar, Vinay NarwalAbstractUrea is the major end product of nitrogen metabolism in humans, which is eliminated from the body mainly by the kidneys through urine but is also secreted in body fluids such as blood and saliva. Its level in urine ranges from 7–20 mg/dL, which drastically rises under patho-physiological conditions thus providing key information of renal function and diagnosis of various kidney and liver disorders. Increase in urea levels in blood, also referred to as azotemia or urem...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
Authors: Madievsky R Abstract Type 2 diabetes mellitus often goes hand in hand with cardiovascular and renal comorbidities. Stroke, myocardial infarction, heart failure, and chronic kidney disease are high-risk complications of type 2 diabetes that contribute to morbidity and mortality. Recent clinical trials have uncovered evidence that certain antidiabetic agents may confer cardiovascular and/or renal benefits such as reduced cardiovascular and all-cause mortality and reduced need for renal replacement therapy. Two landmark trials in particular, EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcomes, and Mortal...
Source: The Permanente journal - Category: General Medicine Tags: Perm J Source Type: research
Authors: Martin WP, Docherty NG, Le Roux CW Abstract INTRODUCTION: Cardiovascular and renal disease accounts for a substantial proportion of the morbidity and mortality associated with obesity and type 2 diabetes mellitus (T2DM). Bariatric surgery is associated with improved long-term cardiovascular and renal outcomes. Areas covered: All major case-control, cohort, and randomized controlled trial studies of bariatric surgery in adults with T2DM were screened and data on prespecified cardiovascular and renal outcomes collated. Bariatric surgery reduces all-cause mortality and risk of cardiovascular disease, albuminu...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Research, published in theClinical Journal of the American Society of Nephrology, suggests that premenopausal women who have had their ovaries removed are at greater risk of developing chronic kidney disease, possibly due to low levels of oestrogen.Medpage Today
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
Objective: We aimed to investigate the relationship of BMI and waist circumference with the development of chronic kidney disease (CKD). Methods: A total of 12 672 hypertensive patients with estimated glomerular filtration rate (eGFR) at least 60 ml/min per 1.73 m2 from the renal sub-study of the China Stroke Primary Prevention Trial (CSPPT) were included. The primary outcome was the development of CKD, defined as a decrease in eGFR of at least 30% and to a level of less than 60 ml/min per 1.73 m2 at the exit visit, or end-stage renal disease. A secondary outcome was rapid renal function decline, defined as ...
Source: Journal of Hypertension - Category: Cardiology Tags: ORIGINAL PAPERS: Obesity Source Type: research
Dr Bansal reviews several studies that evaluate the safety of metformin in patients with chronic kidney disease.Medscape Nephrology
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Nephrology Viewpoint Source Type: news
(MedPage Today) -- Researchers suggest increased risk due to estrogen deprivation
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news
More News: American Health | Biotechnology | Chronic Kidney Disease | Health Management | Urology & Nephrology